Diagnostic and Prognostic Validity of Golgi Protein 73 in Hepatocellular Carcinoma

Özkan, Hasan; Erdal, Harun; Tutkak, Hüseyin; Karaeren, Zihni; Yakut, Mustafa; Yüksel, Osman; Köklü, Seyfettin

doi:10.1159/000320379

Cited by 44 publications

(36 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is not in accordance with another study that stated that there was no correlation between GP73 levels and other prognostic parameters including tumor size [24]. This is not in accordance with another study that stated that there was no correlation between GP73 levels and other prognostic parameters including tumor size [24].…”

Section: Figurecontrasting

confidence: 78%

Can we use GP73 as a biomarker for the detection of hepatocellular carcinoma?

Omran¹,

Esmat²,

Sedrac³

et al. 2011

Egyptian Liver Journal

View full text Add to dashboard Cite

Background and aim Hepatocellular carcinoma (HCC) is one of the top five leading causes of death in Egypt and its prevalence is increasing in the next 10-20 years. We aimed to detect the serum Golgi protein 73 (GP73) in patients with cirrhosis and with HCC, and to determine its sensitivity and specificity as a screening tool for the detection of HCC in this study. Patients and methods Serum GP73 was estimated in 93 participants (patients with HCC, patients with cirrhosis, and healthy controls). Results GP73 was elevated in patients with HCC and liver cirrhosis; serum level was very high in HCC patients (P < 0.01) when compared with the other studied groups. GP73 had sensitivity of 76%, specificity of 75%, at a cut-off value of 16.2 ng/ml with area under the receiver operator characteristic of 0.825 when compared with a-fetoprotein that showed a sensitivity of 63%, specificity of 43% at a cut-off value of 16.5 ng/ml and area under the receiver operator characteristic of 0.611. By combining a-fetoprotein and GP73 for the diagnosis of HCC, sensitivity and specificity were (93 and 25%), respectively. There is a significant positive correlation between diameter of the focal lesion and GP73 (P = 0.01 and r = 0.071). Nonsignificant positive correlation was detected as regards serum GP73 and the number of HCC. Conclusion GP73 can be used as a screening tool for the detection of HCC. Moreover, it shows a higher serum level with larger lesions.Receiver operating characteristic curve for GP73 and a-fetoprotein in the hepatocellular carcinoma group. Figure 3Correlation between GP73 and the size of hepatocellular carcinoma; HLF, hepatic focal lesion.Using GP73 for the detection of HCC Omran et al. 45

show abstract

Section: Figurecontrasting

confidence: 78%

Can we use GP73 as a biomarker for the detection of hepatocellular carcinoma?

Omran¹,

Esmat²,

Sedrac³

et al. 2011

Egyptian Liver Journal

View full text Add to dashboard Cite

show abstract

“…The former two are semiquantitative and laborious, but the results of ELISA are disappointing. Six studies [18,21,23,24,27,33] using ELISA method failed to find significant elevation of serum GP73 in HCC groups compared with that in liver cirrhosis groups. Recently described GP73-specific serum autoantibodies might interfere with ELISA analysis.…”

Section: Discussionmentioning

confidence: 99%

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

et al. 2012

View full text Add to dashboard Cite

BackgroundsThere have been conflicting reports about serum golgi protein 73 (GP73) as one of the most promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC.MethodsAfter a systematic review of related studies, sensitivity, specificity and other measures about the accuracy of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve analysis was used to summarize the overall test performance.ResultsEight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs. 70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87).ConclusionsThe current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.

show abstract

“…One of the proteins identified in the serum of woodchucks with cancer and subsequently in the serum of people with HCC was golgi-proteins 73 (GP73). This protein has subsequently been analyzed in over 10,000 individuals with liver disease(Block et al, 2005b; Gu et al, 2009; Hann et al, 2010; Hu et al, 2010; Iftikhar et al, 2004; Jiang and Zhou, 2012; Liu et al, 2011; Maitra and Thuluvath, 2004; Malaguarnera et al, 2010; Mao et al, 2010; Mao et al, 2008; Marrero et al, 2005; Morota et al, 2011a; Ozkan et al, 2011; Riener, 2011; Riener et al, 2009; Schwegler et al, 2005; Shi et al, 2011; Sun et al, 2011; Tan, 2007; Tan et al, 2009; Tian et al, 2011; Wang et al, 2011a; Wang et al, 2009b; Wang et al, 2011b; Xu et al, 2011; Yamamoto et al, 2010; Zhao et al, 2010; Zhou et al, 2012) and for the most part, shown improved performance in the detection of HCC as compared to AFP. However, in several studies, GP73 either was either not elevated in HCC versus cirrhosis (Morota et al, 2011a; Riener et al, 2009) or was no better than AFP at differentiating HCC from cirrhosis.…”

Section: Glycomic Methodologies For the Identification Of Biomarkers mentioning

confidence: 99%

Glycosylation and Liver Cancer

Mehta

Herrera

Block

2015

Advances in Cancer Research

117

View full text Add to dashboard Cite

Liver cancer is the 5th most common cancer, but the 2nd leading cause of cancer death, in the world, with more than 700,000 fatalities annually. The major etiology of liver cancer is infection with an hepatotropic virus such as hepatitis B virus (HBV) or hepatitis C virus infection (HCV). While chronic viral infection remains the main cause of liver disease and risk of HCC, rates of non –viral associated HCC are occurring at an alarmingly increasing rate. Like many cancers, survival rates are closely associated with time of detection. If HCC is caught early, survival rates can be as high as 50%. Regrettably, most cases of HCC are caught late where survival rates can be as low as 2–7%. Thus, there has been great interest in discovering serum biomarkers that could be used to identify those with HCC. To this end, many groups have examined the N-linked glycans to identify changes that occur with HCC. As the liver secretes the vast majority of proteins into the serum, this has often been a starting point for study. In serum, alterations in core fucosylation, outer-arm fucosylation, increased sialylation and glycan branching have been observed in patients with HCC. Similar findings have been found directly in HCC tissue suggesting that these glycan changes may play a role in tumor formation and development.

show abstract

Diagnostic and Prognostic Validity of Golgi Protein 73 in Hepatocellular Carcinoma

Cited by 44 publications

References 42 publications

Can we use GP73 as a biomarker for the detection of hepatocellular carcinoma?

Can we use GP73 as a biomarker for the detection of hepatocellular carcinoma?

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

Glycosylation and Liver Cancer

Contact Info

Product

Resources

About